Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology programs into a new public company ("SpinCo")

Clear path forward aligned with FDA following pre-BLA meeting for del-zota, with BLA submission planned for 2026

See Full Page